Themis Biosyn shares jump after signing pact to acquire Sanofi’s anti-TB brands

On 2026-04-24, Gujarat Themis Biosyn signed an asset purchase agreement to acquire Sanofi’s portfolio of anti-tuberculosis and anti-infective brands. The deal was reported from Mumbai and was presented as a step toward a seamless transition and continuity of supply to patients globally.